Mission impossible? Caveats in interpreting and comparing long-term efficacy in biologic studies for moderate-to-severe plaque psoriasis
Authors: Langley RG, Egeberg A, Gooderham M, Bissonnette R, Ringuet J, Kalia S, Park-Wyllie L, Abbarin N, Tran D, Zara A, Yang YW, Strober B. Read more on pubmed
ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis
Authors: Guttman-Yassky E, Simpson E, Bissonnette R, Eichenfield LF, Kabashima K, Luna PC, Hercogová JT, Spelman L, Worm M, Esfandiari E, Arai T, Mano H, Charuworn P, Wang A, Kricorian G. Read more on pubmed
Longitudinal integrated proteomic and metabolomic skin changes in patients with atopic dermatitis treated with dupilumab.
Authors: Goleva E, Berdyshev E, Kreimer S, Reisz JA, D’Alessandro A, Bronova I, Lyubchenko T, Richers BN, Hall CF, Xiao O, Bronoff AS, Bafna S, Agueusop I, Gloaguen E, Zahn J, Bissonnette R, Zhang A, Leung DYM. Read more on pubmed
Skin Tape Stripping Reveals Distinct Biomarker Profiles in Chronic Hand Eczema of Patients With and Without Comorbid Atopic Dermatitis
Authors: Bar J, Del Duca E, David E, Bose S, Chefitz G, Brunner PM, Bissonnette R, Guttman-Yassky E. Read more on pubmed
A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2-11 Years with Moderate to Severe Atopic Dermatitis
Date: 2024-11-17 Authors: Linda Stein Gold, Robert Bissonnette, Seth Forman, Andrea Zaenglein, YuTzu Kuo, Brett Angel, Xuejun Chen, Howard Kallender, Amy S Paller Category: Dermatitis (all types), Eczema Background: Ruxolitinib cream has demonstrated anti-inflammatory and antipruritic activity and was well tolerated in a phase 3 study in patients aged 2-11 years with mild to moderate atopic dermatitis (AD). Objective: This […]
FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis
Date: 2024-11-14 Authors: Laura K Ferris 1, Jerry Bagel2, Yu-Huei Huang3, Andrew E Pink4, Stephen K Tyring5, Georgios Kokolakis6, Amy M DeLozier7, Shu Li8, Yaung-Kaung Shen8, Charles Iaconangelo8, Takayuki Ota7, Robert Bissonnette9 Category: Psoriasis Background: More patients with moderate-to-severe plaque psoriasis achieved responses with JNJ-77242113, a targeted oral peptide inhibiting interleukin-23 receptor signaling, versus placebo (PBO) at week (W)16 of the phase 2 FRONTIER-1 study. Objective: FRONTIER-2, a long-term extension of […]
Hand Eczema. Part 1: epidemiology, pathogenesis, diagnosis and work-up
Date: 2024-10-05 Authors:Robert Bissonnette 1, Tove Agner2, Sonja Molin3, Emma Guttman-Yassky4 Category: Eczema Read more on pubmed
Treat-to-Target Outcomes With Tapinarof Cream 1% in Phase 3 Trials for Plaque Psoriasis
Date: 2024-10-01 Authors: April W Armstrong 1, Robert Bissonnette 1, Raj Chovatiya 1, Tina Bhutani 1, Philip M Brown 1, Anna M Tallman 1, Kim A Papp 1 Category: Psoriasis Read more on pubmed
Hand Eczema. Part 2: Prevention, management, and treatment
Date: 2024-9-11 Authors:Robert Bissonnette 1, Tove Agner2, James S Taylor3, Sonja Molin4, Emma Guttman-Yassky5 Category: Eczema Read more on pubmed
A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with nonpustular palmoplantar involvement
Date: 2024-08-30 Authors: Mark Lebwohl 1, Michael Bukhalo 2, Linda Stein Gold 3, Brad Glick 4, Mar Llamas-Velasco 5, Samuel Sanchez-Rivera 6, Anqi Pan 7, Tianyu Zhan 7, Leonidas Drogaris 7, Kevin Douglas 7, Greg St John 7, Ramon Espaillat 7, Robert Bissonnette 8 Category: Psoriasis Background: In plaque psoriasis, palmoplantar areas are more difficult to treat. Objective: Evaluate the safety and efficacy of risankizumab (RZB) versus placebo (PBO) for the treatment of palmoplantar psoriasis. Read more on pubmed
